Amanote Research
Register
Sign In
Osteoporosis Drug Treatment: Duration and Management After Discontinuation. A Position Statement From the SVGO/ASCO
Swiss Medical Weekly
- Switzerland
doi 10.4414/smw.2017.14484
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Date
August 16, 2017
Authors
Unknown
Publisher
EMH Swiss Medical Publishers, Ltd.
Related search
Comment on the Central Drug Authority’s Position Statement on Cannabis
South African Medical Journal
Medicine
Denosumab: A Promising Drug for the Prevention and Treatment of Osteoporosis
Women's Health
Medicine
The British Guidelines on Asthma Management * 1995 Review and Position Statement
Thorax
Pulmonary
Respiratory Medicine
The Treatment of Anal Fistula: Second ACPGBI Position Statement - 2018
Colorectal Disease
Gastroenterology
Abrupt Regression of a Meningioma After Discontinuation of Cyproterone Treatment
American Journal of Neuroradiology
Medicine
Nuclear Medicine
Neurology
Imaging
Radiology
Relationship Between the Timing of Relapse and Plasma Drug Levels Following Discontinuation of Cariprazine Treatment in Patients With Schizophrenia: Indirect Comparison With Other Second-Generation Antipsychotics After Treatment Discontinuation
Neuropsychiatric Disease and Treatment
Medical Treatment With Somatostatin Analogues in Acromegaly: Position Statement
The Korean Journal of Medicine
Evaluation and Management of Skeletal Health in Celiac Disease: Position Statement
Canadian Journal of Gastroenterology
Effects of Teriparatide in Patients With Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment From the European Extended Forsteo® Observational Study (ExFOS)
Calcified Tissue International
Endocrinology
Orthopedics
Sports Medicine
Metabolism
Diabetes
